ARK Investment Management LLC Increases Position in Repare Therapeutics Inc. (NASDAQ:RPTX)

ARK Investment Management LLC increased its stake in Repare Therapeutics Inc. (NASDAQ:RPTX) by 7.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,821,560 shares of the company’s stock after acquiring an additional 200,677 shares during the period. ARK Investment Management LLC owned about 6.70% of Repare Therapeutics worth $20,597,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Barclays PLC purchased a new position in Repare Therapeutics in the second quarter worth $36,000. Exchange Traded Concepts LLC boosted its position in Repare Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 13,585 shares of the company’s stock valued at $99,000 after buying an additional 3,445 shares during the period. Harbor Capital Advisors Inc. boosted its position in Repare Therapeutics by 13.8% during the third quarter. Harbor Capital Advisors Inc. now owns 42,085 shares of the company’s stock valued at $508,000 after buying an additional 5,101 shares during the period. Raymond James Financial Services Advisors Inc. purchased a new stake in Repare Therapeutics during the third quarter valued at about $149,000. Finally, Blackstone Inc. raised its stake in shares of Repare Therapeutics by 14.9% during the third quarter. Blackstone Inc. now owns 25,957 shares of the company’s stock valued at $314,000 after acquiring an additional 3,362 shares during the last quarter. 85.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on RPTX. Bloom Burton downgraded shares of Repare Therapeutics from a “buy” rating to an “accumulate” rating in a research note on Tuesday, February 13th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Repare Therapeutics in a research note on Wednesday, February 21st.

Repare Therapeutics Price Performance

RPTX stock opened at $4.67 on Thursday. Repare Therapeutics Inc. has a 1 year low of $3.08 and a 1 year high of $13.85. The firm has a 50-day moving average of $6.33 and a 200 day moving average of $6.60.

Repare Therapeutics (NASDAQ:RPTX) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.11). Repare Therapeutics had a negative return on equity of 39.82% and a negative net margin of 183.43%. The company had revenue of $13.05 million during the quarter, compared to the consensus estimate of $15.92 million. On average, sell-side analysts expect that Repare Therapeutics Inc. will post -2.74 EPS for the current fiscal year.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.